For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
As a short-acting amnestic agent, propofol features rapid recovery and few adverse effects. And it has been widely used in the maintenance of general anesthesia and sedation for critically ill patients. Generally used together with spinal anesthesia, epidural anesthesia, neuromuscular-blocking drug, inhaled anaesthetic and pain killer, propofol reports no imcompatibility.
Main varieties of anaesthetic are lidocaine, sevoflurane and propofol, among which both sevoflurane and propofol reached its sales peak of USD 1.16 billion and USD 500 million in 2004 in global market. Propogol market in China has kept expanding despite its shrinking global counterpart. As operation number keeps rising in China, anaesthetic sales grows too, leading to a huge potential market.
As an important link of surgery, anesthesia is critical to surgery success and patient’s life. Three broad categories of anesthesia exist: general anesthesia, spinal anesthesia and regional anesthesia, among which general anesthesia dominates the market due to its high price. As the best seller in anaesthetic agents, propofol has been widely used in Chinese hospitals.
As a short-acting, intravenously administered amnestic agent with rapid onset and recovery, propofol has been included in the National List of Essential Medicines. According to CRI’s market survey, the sales value of propofol in China rose from less than CNY 200 million in 2005 to over CNY 800 million in 2014 and CAGR during this period reached 18.5%. And propofol products available in the Chinese market mainly come from AstraZeneca (Italy), Fresenius Kabi, Libang Pharmaceutical Group, Sichuan Shule Pharmaceutical Co., Ltd and B. Braun (Germany), among which AstraZeneca (Italy) had the largest market share of nearly 60% for sales value in 2014.
As operation number keeps rising in China, the demand for propofol is expected to grow in the next few years.
Readers can get at least the following information through this report:
- market size of propofol in China
- competitive landscape of propofol market in China
- price of propofol made by different enterprises in China
- market outlook of propofol in China
The author suggests the following groups of people purchase this report:
- Pharmaceutical Manufacturers
- investors/research institutions interested in Chinese medicine market
- any interest in Chinese medicine market, please contact CRI for customized survey service
Companies Mentioned
AstraZeneca; Fresenius Kabi; Libang Pharmaceutical Group; Sichuan Shule Pharmaceutical Co., Ltd; B. Braun